Impact Of Chronic Hepatitis C Infectionand Liver Metastasis On Survival Outcome Of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (nsclc) Patient Treated With First-Line Gefetinib In Real-World Practice

被引：0
|
作者：
Yao, Z. -H.
Liao, W. -Y.
Ho, C. -C.
Chen, K. -Y.
Shih, J. -Y.
Chen, J. -S.
Lin, Z. -Z.
Lin, C. -C.
Yang, J. -H.
Yu, C. -J.
机构：
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4272
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer
    Laura Ortega-Granados, Ana
    Artal-Cortes, Angel
    Aguiar-Bujanda, David
    Oramas, Juana
    Luis Firvida, Jose
    De Castro, Javier
    Campillo Fuentes, Juana
    Gordo, Rocio
    Galan, Raquel
    Trigo, Jose
    ANTICANCER RESEARCH, 2019, 39 (03) : 1317 - 1328
  • [22] Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)(vol 186 ,107426, 2023)
    Sakata, Yoshihiko
    Saito, Go
    Sakata, Shinya
    Oya, Yuko
    Tamiya, Motohiro
    Suzuki, Hidekazu
    Shibaki, Ryota
    Okada, Asuka
    Yokoyama, Toshihide
    Matsumoto, Hirotaka
    Otsuki, Taiichiro
    Sato, Yuki
    Junji, Uchida
    Tsukita, Yoko
    Inaba, Megumi
    Ikeda, Hideki
    Arai, Daisuke
    Maruyama, Hirotaka
    Hara, Satoshi
    Tsumura, Shinsuke
    Morinaga, Jun
    Sakagami, Takuro
    LUNG CANCER, 2024, 188
  • [23] Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
    Schuler, A.
    Huser, J.
    Schaer, S.
    Schmid, S.
    Scherz, A.
    Gautschi, O.
    Mauti, L. A.
    Von Briel, T.
    Waibel, C.
    De Nicola, L. Wannesson
    Pankovics, J.
    Mark, M. T.
    Rothschild, S. I.
    Addeo, A.
    Janthur, W-D.
    Siano, M.
    Britschgi, C.
    Frueh, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1585
  • [24] Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival
    Farris, M. S.
    Larkin-Kaiser, K. A.
    Scory, T.
    Boyne, D.
    Wilner, K. D.
    Pastel, M.
    Cappelleri, J. C.
    Ivanova, J. I.
    FUTURE ONCOLOGY, 2020, 16 (36) : 3107 - 3116
  • [25] Real-world dose adjustment study of first-line afatinib in pts with EGFR mutation-positive (EGFRm plus ) advanced NSCLC.
    Halmos, Balazs
    Tan, Eng-Huat
    Lee, Min Ki
    Foucher, Pascal
    Hsia, Te-Chun
    Hochmair, Maximilian J.
    Griesinger, Frank
    Hida, Toyoaki
    Kim, Edward S.
    Melosky, Barbara L.
    Maerten, Angela
    Costa, Enric Carcereny
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome
    Tiefenbacher, Andreas
    Pirker, Robert
    JOURNAL OF THORACIC DISEASE, 2017, 9 (11) : 4208 - 4211
  • [27] First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
    Holleman, Marscha S.
    van Tinteren, Harm
    Groen, Harry J. M.
    Al, Maiwenn J.
    Uyl-de Groot, Carin A.
    ONCOTARGETS AND THERAPY, 2019, 12 : 1413 - 1421
  • [28] Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland - real-world data
    Brzozowska, Melania
    Wierzba, Waldemar
    Szafraniec-Burylo, Sylwia
    Czech, Marcin
    Majkut, Gabriela
    Polowinczak-Przybylek, Joanna
    Potemski, Piotr
    Sliwczynski, Andrzej
    ARCHIVES OF MEDICAL SCIENCE, 2021, 17 (06) : 1618 - 1627
  • [29] Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA
    Li, Yulin
    Appius, Anita
    Pattipaka, Thirupathi
    Feyereislova, Andrea
    Cassidy, Adrian
    Ganti, Apar Kishor
    PLOS ONE, 2019, 14 (01):
  • [30] Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients
    Wu, Ting-Hui
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Liao, Wei-Yu
    Ho, Chao-Chi
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Yang, James Chih-Hsin
    CLINICAL LUNG CANCER, 2018, 19 (03) : E361 - E372
12345